Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that influenza drug market sales will reach $2.5 billion in 2012. According to a new Pharmacor study entitled Influenza, MedImmune's FluMist and one other intranasal vaccine will account for 60% of the market in 2012.

"MedImmune's FluMist, the first intranasal vaccine and first live- attenuated vaccine for influenza, has been approved by the FDA and has entered the market in time for the 2003/2004 influenza season," said Jason LaBonte, Ph.D., analyst at Decision Resources. "FluMist's launch signals an abrupt upward shift in the influenza market, as experts indicate that both physicians and patients would greatly prefer a vaccine that is not delivered by injection."

About Influenza

Despite influenza's high annual incidence and its potential to cause significant morbidity and mortality, the influenza market has exhibited slow growth due to disappointing antiviral sales and commodity-priced vaccines. However, with the launch of premium-priced novel vaccines that can be delivered by intranasal sprays or transdermal patches, the influenza market is poised to expand significantly.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Influenza is an Infectious Disease study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., 1-781-296-2563,
emarshall@dresources.com

Female Sexual Dysfunction Drug Market to Grow 10% From 2002 to 2007

View Now